{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:36:28Z","timestamp":1788471388533,"version":"build-2803163510"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neisseria gonorrhoeae has developed resistance to every class of antibiotics historically used in its treatment, undermining current therapeutic options. This review systematically assessed documented treatment failures with ceftriaxone, the recommended antibiotic in many settings. Thirty-three cases of probable or confirmed ceftriaxone treatment failure were identified, with only 8 meeting the European Centre for Disease Prevention and Control criteria for confirmed failure. All confirmed cases were in heterosexuals and most involved pharyngeal infections; a site associated with limited drug penetration and reduced diagnostic sensitivity. Although ceftriaxone-resistant strains are increasingly prevalent globally\u2014particularly in Asia\u2014confirmed failures were reported almost exclusively from high-income countries with robust surveillance and diagnostics, suggesting significant under-reporting elsewhere. Inconsistent treatment regimens, heterogeneous definitions of treatment failures, and limited access to culture diagnostics hamper accurate detection of true clinical failures. These findings underscore the urgent need for standardized definitions, improved global reporting infrastructure, and measures to preserve ceftriaxone efficacy while new treatments are developed.<\/jats:p>","DOI":"10.1093\/cid\/ciaf532","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:00:22Z","timestamp":1758801622000},"page":"S223-S230","source":"Crossref","is-referenced-by-count":6,"title":["The Invisible Tide of\n                    <i>Neisseria gonorrhoeae<\/i>\n                    Treatment Failures: A Review and Commentary"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3560-1968","authenticated-orcid":false,"given":"Lucy","family":"Fagan","sequence":"first","affiliation":[{"name":"Sexually Transmitted Infections Reference Laboratory, UK Health Security Agency , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Alexander","sequence":"additional","affiliation":[{"name":"Sexually Transmitted Infections Reference Laboratory, UK Health Security Agency , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-403X","authenticated-orcid":false,"given":"Helen","family":"Fifer","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, STI & HIV Division, UK Health Security Agency , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2026010808424610800_ciaf532-B1","volume-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016\u20132021: actions for impact","author":"World Health Organization","year":"2021"},{"key":"2026010808424610800_ciaf532-B2","volume-title":"Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022\u20132030","author":"World Health Organization","year":"2022"},{"key":"2026010808424610800_ciaf532-B3","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3201\/eid3007.240354","article-title":"World health organization enhanced gonococcal antimicrobial surveillance programme, Cambodia, 2023","volume":"30","author":"Ouk","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"2026010808424610800_ciaf532-B4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.15585\/mmwr.mm7312a2","article-title":"Ceftriaxone-resistant gonorrhea\u2014China, 2022","volume":"73","author":"Zhu","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026010808424610800_ciaf532-B5","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1093\/jac\/dkae369","article-title":"Ceftriaxone-resistant Neisseria gonorrhoeae detected in England, 2015\u201324: an observational analysis","volume":"79","author":"Fifer","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026010808424610800_ciaf532-B6","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2217\/fmb.12.117","article-title":"Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea","volume":"7","author":"Unemo","year":"2012","journal-title":"Future Microbiol"},{"key":"2026010808424610800_ciaf532-B7","volume-title":"Available at Updated recommendations for the treatment of Neisseria gonorrhoeae, Chlamydia trachomatis, and Treponema pallidum and new recommendations on syphilis testing and partner services","author":"World Health Organization Global HIV, Hepatitis and STIs Programmes Guidelines Review Committee","year":"2024"},{"key":"2026010808424610800_ciaf532-B8","doi-asserted-by":"publisher","DOI":"10.1177\/09564624251345195","article-title":"British association of sexual health and HIV UK national guideline for the management of infection with Neisseria gonorrhoeae, 2025 [manuscript published online ahead of print 31 May 2025]","author":"Fifer","year":"2025","journal-title":"Int J STD AIDS"},{"key":"2026010808424610800_ciaf532-B9","volume-title":"Recommandations de prise en charge des personnes infect\u00e9es par Neisseria gonorrhoeae","author":"Haute Autorit\u00e9 de sant\u00e9 (HAS)","year":"2025"},{"key":"2026010808424610800_ciaf532-B10","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/cid\/ciac043","article-title":"Management of Neisseria gonorrhoeae in the United States: summary of evidence from the development of the 2020 gonorrhea treatment recommendations and the 2021 centers for disease control and prevention sexually transmitted infection treatment guidelines","volume":"74","author":"Barbee","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026010808424610800_ciaf532-B11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/0956462420948739","article-title":"Background review for the \u20182020 European guideline for the diagnosis and treatment of gonorrhoea in adults\u2019","volume":"32","author":"Unemo","year":"2021","journal-title":"Int J STD AIDS"},{"key":"2026010808424610800_ciaf532-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajog.2016.08.008","article-title":"Sexually transmitted diseases and infertility","volume":"216","author":"Tsevat","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"2026010808424610800_ciaf532-B13","volume-title":"Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae","author":"World Health Organization Global HIV, Hepatitis and STIs Programmes Guidelines Review Committee","year":"2012"},{"key":"2026010808424610800_ciaf532-B14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/OLQ.0000000000000980","article-title":"Proportion of incident human immunodeficiency virus cases among men who have sex with men attributable to gonorrhea and chlamydia: a modeling analysis","volume":"46","author":"Jones","year":"2019","journal-title":"Sex Transm Dis"},{"key":"2026010808424610800_ciaf532-B15","volume-title":"Managing incidents of ceftriaxone-resistant Neisseria gonorrhoeae in England - GOV.UK","author":"UK Health Security Agency","year":"2022"},{"key":"2026010808424610800_ciaf532-B16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/OLQ.0000000000002116","article-title":"Minimum inhibitory concentrations of extended-spectrum cephalosporins: a systematic review and meta-analysis of Neisseria gonorrhoeae treatment failures","volume":"52","author":"Miari","year":"2025","journal-title":"Sex Transm Dis"},{"key":"2026010808424610800_ciaf532-B17","volume-title":"Response plan to control and manage the threat of multi- and extensively drug-resistant gonorrhoea in Europe\u20142019 update","author":"European Centre for Disease Prevention and Control (ECDC)","year":"2019"},{"key":"2026010808424610800_ciaf532-B18","doi-asserted-by":"crossref","first-page":"1800323","DOI":"10.2807\/1560-7917.ES.2018.23.27.1800323","article-title":"Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018","volume":"23","author":"Eyre","year":"2018","journal-title":"Euro Surveill"},{"key":"2026010808424610800_ciaf532-B19","doi-asserted-by":"crossref","first-page":"1900147","DOI":"10.2807\/1560-7917.ES.2019.24.10.1900147","article-title":"Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018","volume":"24","author":"Eyre","year":"2019","journal-title":"Euro Surveill"},{"key":"2026010808424610800_ciaf532-B20","first-page":"552","article-title":"Emerging international strain of multidrug-resistant Neisseria gonorrhoeae: infection in a man with urethral discharge","volume":"65","author":"Smyczek","year":"2019","journal-title":"Can Fam Physician"},{"key":"2026010808424610800_ciaf532-B21","doi-asserted-by":"crossref","first-page":"1800264","DOI":"10.2807\/1560-7917.ES.2018.23.21.1800264","article-title":"Multidrug-resistant Neisseria gonorrhoeae failing treatment with ceftriaxone and doxycycline in France, November 2017","volume":"23","author":"Poncin","year":"2018","journal-title":"Euro Surveill"},{"key":"2026010808424610800_ciaf532-B22","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMc1512757","article-title":"Failure of dual antimicrobial therapy in treatment of gonorrhea","volume":"374","author":"Fifer","year":"2016","journal-title":"N Engl J Med"},{"key":"2026010808424610800_ciaf532-B23","doi-asserted-by":"crossref","first-page":"19792","DOI":"10.2807\/ese.16.06.19792-en","article-title":"Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010","volume":"16","author":"Unemo","year":"2011","journal-title":"Euro Surveill"},{"key":"2026010808424610800_ciaf532-B24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3201\/eid1701.100397","article-title":"Ceftriaxone-resistant Neisseria gonorrhoeae, Japan","volume":"17","author":"Ohnishi","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"2026010808424610800_ciaf532-B25","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1093\/jac\/dkae327","article-title":"Neisseria gonorrhoeae treatment failure to the recommended antibiotic regimen-Qu\u00e9bec, Canada, 2015\u201319","volume":"79","author":"Blouin","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026010808424610800_ciaf532-B26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/OLQ.0000000000000712","article-title":"Frequency of nucleic acid amplification test positivity among men who have sex with men returning for a test-of-cure visit 7 to 30 days after treatment of laboratory-confirmed Neisseria gonorrhoeae infection at 2 public sexual health clinics, New York City, 2013 to 2016","volume":"45","author":"Okah","year":"2018","journal-title":"Sex Transm Dis"},{"key":"2026010808424610800_ciaf532-B27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/cid\/ciu873","article-title":"Persistence of Neisseria gonorrhoeae DNA following treatment for pharyngeal and rectal gonorrhea is influenced by antibiotic susceptibility and reinfection","volume":"60","author":"Bissessor","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026010808424610800_ciaf532-B28","doi-asserted-by":"crossref","first-page":"20862","DOI":"10.2807\/1560-7917.ES2014.19.30.20862","article-title":"Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 Mg) or cefotaxime (500 Mg), Sweden, 2013 and 2014","volume":"19","author":"Golparian","year":"2014","journal-title":"Euro Surveill"},{"key":"2026010808424610800_ciaf532-B29","doi-asserted-by":"crossref","first-page":"20200","DOI":"10.2807\/ese.17.25.20200-en","article-title":"Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011","volume":"17","author":"Unemo","year":"2012","journal-title":"Euro Surveill"},{"key":"2026010808424610800_ciaf532-B30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1071\/SH13077","article-title":"One confirmed and one suspected case of pharyngeal gonorrhoea treatment failure following 500 mg ceftriaxone in Sydney, Australia","volume":"10","author":"Read","year":"2013","journal-title":"Sex Health"},{"key":"2026010808424610800_ciaf532-B31","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/jac\/dkt017","article-title":"Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia","volume":"68","author":"Y Chen","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2026010808424610800_ciaf532-B32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1099\/jmm.0.007641-0","article-title":"Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods","volume":"58","author":"Tapsall","year":"2009","journal-title":"J Med Microbiol"},{"key":"2026010808424610800_ciaf532-B33","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2025-056487","article-title":"Oropharyngeal gonorrhoea infections among young heterosexual users of online sexual health services across the island of Ireland [manuscript published online ahead of print 2 June 2025]","author":"Harrison","year":"2025","journal-title":"Sex Transm Infect"},{"key":"2026010808424610800_ciaf532-B34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/OLQ.0000000000001760","article-title":"Pharyngeal gonorrhea in heterosexual male and female sex partners of persons with gonorrhea","volume":"50","author":"McLaughlin","year":"2023","journal-title":"Sex Transm Dis"},{"key":"2026010808424610800_ciaf532-B35","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/OLQ.0000000000002157","article-title":"Routine pharyngeal gonorrhea test of cure: is it an effective cephalosporin-resistant gonorrhea control strategy?","volume":"52","author":"Quilter","year":"2025","journal-title":"Sex Transm Dis"},{"key":"2026010808424610800_ciaf532-B36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/cid\/ciz170","article-title":"Widespread use of high-dose ceftriaxone therapy for uncomplicated gonorrhea without reported ceftriaxone treatment failure: results from 5 years of multicenter surveillance data in China","volume":"70","author":"Han","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026010808424610800_ciaf532-B37","author":"Clinical & Laboratory Standards Institute"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/Supplement_5\/S223\/66307192\/ciaf532.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/Supplement_5\/S223\/66307192\/ciaf532.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T13:42:59Z","timestamp":1767879779000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/Supplement_5\/S223\/8417259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":37,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf532","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,15]]},"published":{"date-parts":[[2025,12,15]]}}}